{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:57:15Z","timestamp":1792112235150,"version":"4.4.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["BCRF-24-167"],"award-info":[{"award-number":["BCRF-24-167"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014547","name":"Parker Institute for Cancer Immunotherapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016520-46"],"award-info":[{"award-number":["P30CA016520-46"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009634","name":"Susan G. Komen","doi-asserted-by":"publisher","award":["SAC232145"],"award-info":[{"award-number":["SAC232145"]}],"id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006920","name":"University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"DOI":"10.1038\/s41523-025-00889-7","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T18:54:11Z","timestamp":1768330451000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Agonistic CD40 elicits CD8+ T-cell-dependent primary responses and CD4+ T-cell-dependent long-term immunity in breast cancer"],"prefix":"10.1038","volume":"12","author":[{"given":"Casey","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Lanchoney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu","family":"Maddipatla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nune","family":"Markosyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Ray Fofana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald P.","family":"DeMatteo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Vonderheide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Q.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"889_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"889_CR2","doi-asserted-by":"crossref","unstructured":"Howlader, N. et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J. Natl Cancer Inst. 106, dju055 (2014).","DOI":"10.1093\/jnci\/dju055"},{"key":"889_CR3","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan, H. et al. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N. Engl. J. Med. 377, 1836\u20131846 (2017).","journal-title":"N. Engl. J. Med."},{"key":"889_CR4","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jamaoncol.2018.7147","volume":"5","author":"S Adams","year":"2019","unstructured":"Adams, S. et al. Current landscape of immunotherapy in breast cancer: a review. JAMA Oncol. 5, 1205 (2019).","journal-title":"JAMA Oncol."},{"key":"889_CR5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N. Engl. J. Med. 387, 217\u2013226 (2022).","journal-title":"N. Engl. J. Med."},{"key":"889_CR6","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid, P. et al. Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108\u20132121 (2018).","journal-title":"N. Engl. J. Med."},{"key":"889_CR7","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid, P. et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N. Engl. J. Med. 391, 1981\u20131991 (2024).","journal-title":"N. Engl. J. Med."},{"key":"889_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","volume":"21","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 21, 44\u201359 (2020).","journal-title":"Lancet Oncol."},{"key":"889_CR9","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396, 1817\u20131828 (2020).","journal-title":"Lancet"},{"key":"889_CR10","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med. 382, 810\u2013821 (2020).","journal-title":"N. Engl. J. Med."},{"key":"889_CR11","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s10549-017-4537-5","volume":"167","author":"LY Dirix","year":"2018","unstructured":"Dirix, L. Y. et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res. Treat. 167, 671\u2013686 (2018).","journal-title":"Breast Cancer Res. Treat."},{"key":"889_CR12","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1158\/1078-0432.CCR-17-3452","volume":"24","author":"HS Rugo","year":"2018","unstructured":"Rugo, H. S. et al. Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer. Clin. Cancer Res. 24, 2804\u20132811 (2018).","journal-title":"Clin. Cancer Res."},{"key":"889_CR13","unstructured":"Loi, S. et al. International Breast Cancer Study Group and the Breast International Group. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. Lancet Oncol. 20, 371\u2013382 (2019)."},{"key":"889_CR14","doi-asserted-by":"publisher","first-page":"v104","DOI":"10.1093\/annonc\/mdz242","volume":"30","author":"LA Emens","year":"2019","unstructured":"Emens, L. A. et al. 305O - Overall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC). Ann. Oncol. 30, v104 (2019).","journal-title":"Ann. Oncol."},{"key":"889_CR15","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","volume":"31","author":"S Loi","year":"2013","unstructured":"Loi, S. et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. JCO 31, 860\u2013867 (2013).","journal-title":"JCO"},{"key":"889_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert, C. et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 19, 40\u201350 (2018).","journal-title":"Lancet Oncol."},{"key":"889_CR17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet 51, 202\u2013206 (2019).","journal-title":"Nat. Genet"},{"key":"889_CR18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","volume":"229","author":"R Elgueta","year":"2009","unstructured":"Elgueta, R. et al. Molecular mechanism and function of CD40\/CD40L engagement in the immune system. Immunol. Rev. 229, 152\u2013172 (2009).","journal-title":"Immunol. Rev."},{"key":"889_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","volume":"71","author":"RH Vonderheide","year":"2020","unstructured":"Vonderheide, R. H. CD40 agonist antibodies in cancer immunotherapy. Annu. Rev. Med. 71, 47\u201358 (2020).","journal-title":"Annu. Rev. Med."},{"key":"889_CR20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190673","volume":"217","author":"JH Lin","year":"2020","unstructured":"Lin, J. H. et al. Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis. J. Exp. Med. 217, e20190673 (2020).","journal-title":"J. Exp. Med."},{"key":"889_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.smim.2009.05.010","volume":"21","author":"DY Ma","year":"2009","unstructured":"Ma, D. Y. & Clark, E. A. The role of CD40 and CD154\/CD40L in dendritic cells. Semin. Immunol. 21, 265\u2013272 (2009).","journal-title":"Semin. Immunol."},{"key":"889_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/jlb.67.1.2","volume":"67","author":"C Van Kooten","year":"2000","unstructured":"Van Kooten, C. & Banchereau, J. CD40-CD40 ligand. J. Leukoc. Biol. 67, 2\u201317 (2000).","journal-title":"J. Leukoc. Biol."},{"key":"889_CR23","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1158\/2326-6066.CIR-17-0345","volume":"6","author":"JQ Zhang","year":"2018","unstructured":"Zhang, J. Q. et al. Macrophages and CD8+ T cells mediate the antitumor efficacy of combined CD40 ligation and imatinib therapy in gastrointestinal stromal tumors. Cancer Immunol. Res. 6, 434\u2013447 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"889_CR24","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/31002","volume":"393","author":"SP Schoenberger","year":"1998","unstructured":"Schoenberger, S. P., Toes, R. E. M., Van Der Voort, E. I. H., Offringa, R. & Melief, C. J. M. T-cell help for cytotoxic T lymphocytes is mediated by CD40\u2013CD40L interactions. Nature 393, 480\u2013483 (1998).","journal-title":"Nature"},{"key":"889_CR25","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/30996","volume":"393","author":"SRM Bennett","year":"1998","unstructured":"Bennett, S. R. M. et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393, 478\u2013480 (1998).","journal-title":"Nature"},{"key":"889_CR26","doi-asserted-by":"publisher","first-page":"8022","DOI":"10.1073\/pnas.1918971117","volume":"117","author":"AH Morrison","year":"2020","unstructured":"Morrison, A. H., Diamond, M. S., Hay, C. A., Byrne, K. T. & Vonderheide, R. H. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity. Proc. Natl. Acad. Sci. Usa. 117, 8022\u20138031 (2020).","journal-title":"Proc. Natl. Acad. Sci. Usa."},{"key":"889_CR27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1158\/2326-6066.CIR-14-0215","volume":"3","author":"R Winograd","year":"2015","unstructured":"Winograd, R. et al. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol. Res. 3, 399\u2013411 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"889_CR28","doi-asserted-by":"publisher","first-page":"e1468956","DOI":"10.1080\/2162402X.2018.1468956","volume":"7","author":"DL Bajor","year":"2018","unstructured":"Bajor, D. L. et al. Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. OncoImmunology 7, e1468956 (2018).","journal-title":"OncoImmunology"},{"key":"889_CR29","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","volume":"28","author":"LJ Padr\u00f3n","year":"2022","unstructured":"Padr\u00f3n, L. J. et al. Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat. Med. 28, 1167\u20131177 (2022).","journal-title":"Nat. Med."},{"key":"889_CR30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S1470-2045(20)30532-5","volume":"22","author":"MH O\u2019Hara","year":"2021","unstructured":"O\u2019Hara, M. H. et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 22, 118\u2013131 (2021).","journal-title":"Lancet Oncol."},{"key":"889_CR31","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1470-2045(24)00263-8","volume":"25","author":"J-L Van Laethem","year":"2024","unstructured":"Van Laethem, J.-L. et al. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b\/2 study. Lancet Oncol. 25, 853\u2013864 (2024).","journal-title":"Lancet Oncol."},{"key":"889_CR32","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1038\/oncsis.2016.65","volume":"5","author":"MR Sheen","year":"2016","unstructured":"Sheen, M. R. et al. Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer. Oncogenesis 5, e267 (2016).","journal-title":"Oncogenesis"},{"key":"889_CR33","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1101\/gad.1849509","volume":"23","author":"JE Visvader","year":"2009","unstructured":"Visvader, J. E. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev. 23, 2563\u20132577 (2009).","journal-title":"Genes Dev."},{"key":"889_CR34","doi-asserted-by":"publisher","first-page":"8074","DOI":"10.1002\/cam4.3295","volume":"9","author":"A Le Naour","year":"2020","unstructured":"Le Naour, A., Rossary, A. & Vasson, M. EO771, is it a well-characterized cell line for mouse mammary cancer model? Limit and uncertainty. Cancer Med. 9, 8074\u20138085 (2020).","journal-title":"Cancer Med."},{"key":"889_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01418-1","volume":"20","author":"A Le Naour","year":"2020","unstructured":"Le Naour, A. et al. EO771, the first luminal B mammary cancer cell line from C57BL\/6 mice. Cancer Cell Int. 20, 328 (2020).","journal-title":"Cancer Cell Int."},{"key":"889_CR36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","volume":"33","author":"J Chun","year":"2010","unstructured":"Chun, J. & Hartung, H.-P. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin. Neuropharmacol. 33, 91\u2013101 (2010).","journal-title":"Clin. Neuropharmacol."},{"key":"889_CR37","doi-asserted-by":"publisher","first-page":"5815","DOI":"10.3390\/cancers14235815","volume":"14","author":"SH Omland","year":"2022","unstructured":"Omland, S. H. et al. Feasibility of intratumoral anti-PD1 as treatment of human basal cell carcinoma: an explorative study with adjuvant ablative fractional laser. Cancers 14, 5815 (2022).","journal-title":"Cancers"},{"key":"889_CR38","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1172\/JCI128562","volume":"129","author":"DN Khalil","year":"2019","unstructured":"Khalil, D. N. et al. In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors. J. Clin. Investig. 129, 3435\u20133447 (2019).","journal-title":"J. Clin. Investig."},{"key":"889_CR39","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/ijc.32141","volume":"145","author":"SMM Irenaeus","year":"2019","unstructured":"Irenaeus, S. M. M. et al. First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies. Int. J. Cancer 145, 1189\u20131199 (2019).","journal-title":"Int. J. Cancer"},{"key":"889_CR40","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/14737140.2017.1270208","volume":"17","author":"GL Beatty","year":"2017","unstructured":"Beatty, G. L., Li, Y. & Long, K. B. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Rev. Anticancer Ther. 17, 175\u2013186 (2017).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"889_CR41","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","volume":"31","author":"F Cardoso","year":"2025","unstructured":"Cardoso, F. et al. Pembrolizumab and chemotherapy in high-risk, early-stage, ER+\/HER2- breast cancer: a randomized phase 3 trial. Nat. Med. 31, 442\u2013448 (2025).","journal-title":"Nat. Med."},{"key":"889_CR42","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","volume":"31","author":"S Loi","year":"2025","unstructured":"Loi, S. et al. Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. Nat. Med. 31, 433\u2013441 (2025).","journal-title":"Nat. Med."},{"key":"889_CR43","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1177\/0192623309357074","volume":"38","author":"CN Bennett","year":"2010","unstructured":"Bennett, C. N. & Green, J. E. Genomic analyses as a guide to target identification and preclinical testing of mouse models of breast cancer. Toxicol. Pathol. 38, 88\u201395 (2010).","journal-title":"Toxicol. Pathol."},{"key":"889_CR44","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4103\/1477-3163.91116","volume":"10","author":"S Mohibi","year":"2011","unstructured":"Mohibi, S., Mirza, S., Band, H. & Band, V. Mouse models of estrogen receptor-positive breast cancer. J. Carcinog. 10, 35 (2011).","journal-title":"J. Carcinog."},{"key":"889_CR45","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.137263","volume":"5","author":"AP Huffman","year":"2020","unstructured":"Huffman, A. P., Lin, J. H., Kim, S. I., Byrne, K. T. & Vonderheide, R. H. CCL5 mediates CD40-driven CD4+ T cell tumor infiltration and immunity. JCI Insight 5, e137263 (2020).","journal-title":"JCI Insight"},{"key":"889_CR46","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","volume":"63","author":"R Tokunaga","year":"2018","unstructured":"Tokunaga, R. et al. CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation\u2014a target for novel cancer therapy. Cancer Treat. Rev. 63, 40\u201347 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"889_CR47","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","volume":"50","author":"MT Chow","year":"2019","unstructured":"Chow, M. T. et al. Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 Therapy. Immunity 50, 1498\u20131512.e5 (2019).","journal-title":"Immunity"},{"key":"889_CR48","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.cytogfr.2013.03.001","volume":"24","author":"I Comerford","year":"2013","unstructured":"Comerford, I. et al. A myriad of functions and complex regulation of the CCR7\/CCL19\/CCL21 chemokine axis in the adaptive immune system. Cytokine Growth Factor Rev. 24, 269\u2013283 (2013).","journal-title":"Cytokine Growth Factor Rev."},{"key":"889_CR49","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.cellimm.2004.12.006","volume":"231","author":"K Flanagan","year":"2004","unstructured":"Flanagan, K., Moroziewicz, D., Kwak, H., H\u00f6rig, H. & Kaufman, H. L. The lymphoid chemokine CCL21 costimulates naive T cell expansion and Th1 polarization of non-regulatory CD4+ T cells. Cell Immunol. 231, 75\u201384 (2004).","journal-title":"Cell Immunol."},{"key":"889_CR50","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/8426","volume":"5","author":"RR French","year":"1999","unstructured":"French, R. R., Chan, H. T. C., Tutt, A. L. & Glennie, M. J. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 5, 548\u2013553 (1999).","journal-title":"Nat. Med."},{"key":"889_CR51","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","volume":"181","author":"DY Oh","year":"2020","unstructured":"Oh, D. Y. et al. Intratumoral CD4+ T cells mediate anti-tumor cytotoxicity in human bladder cancer. Cell 181, 1612\u20131625.e13 (2020).","journal-title":"Cell"},{"key":"889_CR52","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","volume":"28","author":"RE Tay","year":"2021","unstructured":"Tay, R. E., Richardson, E. K. & Toh, H. C. Revisiting the role of CD4+ T cells in cancer immunotherapy-new insights into old paradigms. Cancer Gene Ther. 28, 5\u201317 (2021).","journal-title":"Cancer Gene Ther."},{"key":"889_CR53","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.ccell.2025.07.013","volume":"43","author":"JC Osorio","year":"2025","unstructured":"Osorio, J. C. et al. Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. Cancer Cell 43, 1902\u20131916.e9 (2025).","journal-title":"Cancer Cell"},{"key":"889_CR54","doi-asserted-by":"publisher","first-page":"e007117","DOI":"10.1136\/jitc-2023-007117","volume":"11","author":"M Perez-Lanzon","year":"2023","unstructured":"Perez-Lanzon, M. et al. New hormone receptor-positive breast cancer mouse cell line mimicking the immune microenvironment of anti-PD-1 resistant mammary carcinoma. J. Immunother. Cancer 11, e007117 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"889_CR55","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41556-019-0373-7","volume":"21","author":"IS Kim","year":"2019","unstructured":"Kim, I. S. et al. Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms. Nat. Cell Biol. 21, 1113\u20131126 (2019).","journal-title":"Nat. Cell Biol."},{"key":"889_CR56","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1038\/onc.2012.261","volume":"32","author":"CZ Cotrim","year":"2013","unstructured":"Cotrim, C. Z. et al. Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells. Oncogene 32, 2390\u20132402 (2013).","journal-title":"Oncogene"}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00889-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00889-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00889-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:03:18Z","timestamp":1770901398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00889-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["889"],"URL":"https:\/\/doi.org\/10.1038\/s41523-025-00889-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6823527\/v1","asserted-by":"object"}]},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Vonderheide has received consulting fees from BMS, EMD Serono, Grey Wolf Therapeutics and Crossbow Therapeutics, research funding from Revolution Medicines, is an inventor on patents relating to cancer cellular immunotherapy, cancer vaccines, and KRAS immune epitopes, and receives royalties from Children\u2019s Hospital Boston for a licensed research-only monoclonal antibody, but declares no non-financial competing interests. All other authors declare no financial or non-financial competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}